Journal of Virus Eradication最新文献

{"title":"Prevalence and genotype distribution of high-risk human papillomavirus infections among women in selected communities in the Philippines: Results of the defeat HPV study","authors":"Ourlad Alzeus G. Tantengco ,&nbsp;Ian Kim B. Tabios ,&nbsp;Abialbon G. Francisco ,&nbsp;Clarissa L. Velayo ,&nbsp;Ryan C.V. Lintao ,&nbsp;Fresthel Monica M. Climacosa ,&nbsp;Leslie Michelle M. Dalmacio ,&nbsp;Leslie Faye T. Cando ,&nbsp;Glenmarie Angelica S. Perias ,&nbsp;Ronniel Alfred N. Acebes ,&nbsp;Sheriah Laine M. de Paz-Silava","doi":"10.1016/j.jve.2025.100620","DOIUrl":"10.1016/j.jve.2025.100620","url":null,"abstract":"<div><div>Persistent infection with high-risk human papillomavirus (HR HPV) is the necessary cause of cervical cancer. In the Philippines, available data on the prevalence and genotype distribution of HPV infections are limited and largely derived from earlier hospital-based studies. The present study determined the overall and type-specific prevalence of HR HPV infection among women in selected communities in the Philippines, along with the associated sociodemographic and behavioral factors. A total of 1,194 women from two communities were examined. Cervical swabs were collected, and the extracted DNA were analyzed for HPV genotyping through a commercial multiplex real-time PCR assay kit. Sociodemographic information, clinical history, and sexual and reproductive behavior were obtained through an interviewer-administered semi-structured questionnaire. The overall prevalence of HR HPV infection was 11.22 % (95 % CI: 9.56–13.14 %). Women residing in urban areas had 1.62 times higher odds (95 % CI: 1.08–2.42) of HR HPV infection than those in rural areas. Moreover, for every year of delaying vaginal sexual debut, there was a 7 % decrease in the odds of HR HPV infection. HPV 52 was the most prevalent genotype (2.59 %), followed by HPV 16 (1.84 %) and HPV 68 (1.09 %). Multiple HR HPV genotypes were recorded in 23 % of HR HPV-infected women. The most frequent co-infections are HPV 16 + HPV 18, HPV 16 + HPV 52, and HPV 39 + HPV 52. These findings highlight the need for updated surveillance and consideration of local genotype distribution in cervical cancer prevention strategies, such as in HPV DNA testing and HPV vaccination programs.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"12 1","pages":"Article 100620"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Origin, distribution and incidence of human rabies in Côte d’Ivoire from 2013 to 2023","authors":"Konan Yannick ,&nbsp;Kouassi Clémence ,&nbsp;Ossey Carine ,&nbsp;Brou Martial ,&nbsp;Diane Maxime ,&nbsp;Adjogoua Edgard Valery","doi":"10.1016/j.jve.2026.100622","DOIUrl":"10.1016/j.jve.2026.100622","url":null,"abstract":"<div><h3>Background</h3><div>This study aims to describe the epidemiological characteristics of human rabies cases in Côte d’Ivoire over 11-year.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted on all human rabies cases reported from 2013 to 2023. Samples were analyzed by RT-qPCR using primers targeting the nucleoprotein gene according to WHO rabies diagnostic guidelines. Sociodemographic, clinical, and epidemiological data were compiled and analyzed.</div></div><div><h3>Results</h3><div>Hundred and fifty-two (84.44 %) out of hundred and eighty suspected cases were positive, representing an annual average of 14 cases of rabies. Men accounted for 2/3 of suspected cases and 68.42 % of confirmed ones. Patients' average age was 25.98 years. Socio-professional groups most affected were schoolchildren with 28.29 % of cases, farmers (20.39 %), and housekeepers (13.16 %). District of Abidjan, along with Loh-Djiboua, Gbêkê and Haut-Sassandra regions, recorded the highest positivity rates. Most infections (90.8 %) resulted from third-degree contact (bites), mainly to the upper limbs (46.71 %). The spastic form of rabies was predominant (84.87 %). None of the positive patients had been vaccinated. Vectors were mainly wandering dogs (82.24 %).</div></div><div><h3>Conclusion</h3><div>Human rabies remains a major public health concern in Côte d'Ivoire, mainly affecting schoolchildren and mostly located in rural areas. Prevention strategies, including vaccination and control of wandering animals, remain essential.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"12 1","pages":"Article 100622"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146078472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Legal framework reform imperatives for rabies elimination in Bangladesh","authors":"Mujib Rahman ,&nbsp;A.K.M. Dawlat Khan","doi":"10.1016/j.jve.2026.100621","DOIUrl":"10.1016/j.jve.2026.100621","url":null,"abstract":"","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"12 1","pages":"Article 100621"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145926885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of acquired resistance to HIV integrase strand transfer inhibitors (INSTIs) in clinical samples from treatment-experienced patients in Chile, 2012–2023","authors":"P. Ferrer ,&nbsp;V. Ramos ,&nbsp;M. Durán ,&nbsp;D. Maureira ,&nbsp;C. Beltrán ,&nbsp;A. Afani","doi":"10.1016/j.jve.2025.100608","DOIUrl":"10.1016/j.jve.2025.100608","url":null,"abstract":"<div><h3>Background</h3><div>Integrase strand transfer inhibitors (INSTIs) are widely used in HIV treatment, yet few large-scale studies have examined acquired resistance (AR) at the population level. This study assessed the prevalence, patterns, and clinical implications of AR to INSTIs in Chile over a 12-year period.</div></div><div><h3>Methods</h3><div>We analyzed 5266 genotypic sequences from ART-experienced individuals with confirmed virological failure and INSTI-based regimens between 2012 and 2023. Resistance-associated mutations were classified using the Stanford HIVdb algorithm. Resistance trends were compared between pre-pandemic (2012–2019) and post-pandemic (2020–2023) periods.</div></div><div><h3>Results</h3><div>High AR rates were observed for first-generation INSTIs: raltegravir (28 %) and elvitegravir (27.7 %). Lower resistance levels were found for dolutegravir (8.3 %), bictegravir (8.3 %), and cabotegravir (18.7 %). Major resistance mutations included N155H (25.2 %), Q148 H/K/R (17.2 %), and Y143R (14.3 %). Notably, Q148 H/K/R mutations were always found in combination with other major mutations. Subtype-specific differences were observed, with higher first-generation INSTI resistance in subtype F (55.6 %) than in subtype B (23.9 %). Post-pandemic resistance increased significantly for first-generation INSTIs (25 % vs. 31 %, p &lt; 0.05). The mutation N155H, while not impacting DTG or BIC significantly, conferred intermediate resistance to CAB. CAB resistance was detected despite its absence in treatment protocols, likely due to cross-resistance pathways.</div></div><div><h3>Conclusions</h3><div>Acquired INSTIs resistance in Chile is high, especially for first-generation drugs. These findings highlight the need for nationwide molecular surveillance and pre-treatment genotyping, particularly before initiating long-acting regimens such as CAB-LA. Strategic monitoring will be critical to maintaining the efficacy of current and next-generation INSTIs.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"11 4","pages":"Article 100608"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145097797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population immunity to the three serotypes of poliovirus post-interruption of wild poliovirus transmission in Nigeria","authors":"Marycelin Mandu Baba ,&nbsp;Aisha Abba Kawu ,&nbsp;Sadiya Alhaji Bukar ,&nbsp;Musa Sundu Melton ,&nbsp;Abdulwahab Mala ,&nbsp;Ibrahim Salisu ,&nbsp;Bamidele Soji Oderinde","doi":"10.1016/j.jve.2025.100615","DOIUrl":"10.1016/j.jve.2025.100615","url":null,"abstract":"<div><div>The presence of neutralizing antibodies is considered a surrogate marker of protection against the three serotypes of poliovirus. The need to use the Microneutralization test in assessing the neutralizing antibodies to the three serotypes of polioviruses among vaccinated children aged 1–15 years informed this study. Of 400 children tested, 309 (77.3 %), 253 (63.3 %), and 308 (77.0 %) had neutralizing antibodies against P1, P2, and P3, respectively. Only 191 (47.8 %) had neutralizing antibodies against P1P2P3 simultaneously, the global target. Whilst 91 (22.8 %) had no neutralizing antibodies against P1, these children were protected against P2 (23.0 %) and P3 (43.9 %). Similarly, 147 (36.8 %) children had no neutralizing antibodies against P2, but were protected against P1 (66.0 %) and P3 (65.3 %). Furthermore, 52(13 %), 51(12.8 %), and 52 (13.0 %) had no neutralizing antibodies against the combination of P1P3, P1P2, and P2P3, respectively. Only 34 (8.5 %) of the children had no nAb to any of the three serotypes. The optimal number of Polio vaccine doses for effective immunity varied depending on the serotype. Also, gender differences may favor the speed at which children achieve the target antibody titers. Higher antibody titers (1:1280) were observed for P2 and P3, with six of the children having a titer of 1:10240 for P3. The combination of supplementary immunization activities and routine immunization generated a robust immune response across all poliovirus serotypes, in contrast to each of the two. The administrative data and population immunity were not commensurate. New strategies to increase immunity against the P1P2P3 simultaneously in all age groups are urgently required.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"11 4","pages":"Article 100615"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolution of split-protein technologies in virology: From mechanistic discovery and diagnostics to therapeutic promise","authors":"Kai Zhou ,&nbsp;Yingshou Lei ,&nbsp;Yaoqi Zhou ,&nbsp;Jian Zhan","doi":"10.1016/j.jve.2025.100610","DOIUrl":"10.1016/j.jve.2025.100610","url":null,"abstract":"<div><div>The persistent challenge posed by viruses such as HIV, HBV, and SARS-CoV-2 necessitates the continuous evolution of molecular tools for their study and for advancing therapeutic research. Split-protein complementation assays (PCAs), where a reporter protein is divided into two inactive fragments, have evolved from simple reporters of biological events into an increasingly important tool in modern virology. This review traces the evolutionary trajectory of split-protein systems. We begin with their foundational use in mechanistic discovery, where they first visualized viral-host interactions in living cells. We then explore their translation into practical applications, such as high-throughput drug screening and rapid point-of-care diagnostics. A step in this evolution was the development of systematic engineering platforms, dramatically accelerating the creation of novel biosensors. Finally, we discuss the latest frontier: engineering therapeutically active \"split effectors.\" By integrating principles from synthetic biology, these advanced systems can function as programmable logic gates that respond to specific viral signatures. While therapeutic translation remains preclinical, split-protein platforms are emerging as tangible tools for advanced research and potential therapeutic development.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"11 4","pages":"Article 100610"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the HIV/AIDS epidemic in Bangladesh: A comprehensive retrospective analysis of epidemiological trends and sex-specific disparities (1990–2021) with long-term ARIMA forecasting to 2050 for strategic public health planning","authors":"Ibrahim Khalil ,&nbsp;Md Imran Hossain ,&nbsp;Sakib Abrar ,&nbsp;Mst Mahmuda Akter ,&nbsp;Supoma Ghosh Ria ,&nbsp;M Rafiqul Islam","doi":"10.1016/j.jve.2025.100614","DOIUrl":"10.1016/j.jve.2025.100614","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The HIV/AIDS epidemic remains a critical public health challenge in Bangladesh, with complex epidemiological trends and sex-specific disparities requiring detailed investigation to guide effective interventions. This study comprehensively analyzes the temporal dynamics of HIV/AIDS burden from 1990 to 2021 and employs advanced statistical modeling to forecast future trends up to 2050, aiming to inform targeted public health strategies.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Data on Disability-Adjusted Life Years (DALYs), deaths, incidence, prevalence, Years Lived with Disability (YLDs), and Years of Life Lost (YLLs) were sourced from a robust epidemiological database for Bangladesh. Joinpoint regression analysis was utilized to detect significant trend changes, calculating the average annual percent change (AAPC) and annual percent change (APC) with 95 % confidence intervals (CIs). Sex-stratified analyses elucidated disparities between males and females. Autoregressive Integrated Moving Average (ARIMA) models were applied to project age-standardized rates (ASRs) for each metric through 2050, incorporating historical trends and variability to ensure robust predictions.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;From 1990 to 2021, the HIV/AIDS burden in Bangladesh increased significantly across all metrics, with distinct sex-specific patterns. The overall AAPC for DALYs was 19.0332 % (95 % CI: 15.8145, 23.0026, p &lt; 0.000001), with females showing a higher AAPC (21.7252 %, 95 % CI: 18.2308, 25.7026) than males (18.4703 %, 95 % CI: 15.1896, 22.5646). Deaths exhibited a similar trend, with an overall AAPC of 18.9645 % (95 % CI: 15.7008, 23.2166), higher in females (21.8808 %, 95 % CI: 18.4195, 25.9932) than males (18.4655 %, 95 % CI: 15.1992, 22.6832). Incidence rose with an AAPC of 15.7929 % (95 % CI: 11.6467, 19.1922), slightly higher in females (16.2581 %, 95 % CI: 12.1795, 20.0487) than males (15.1639 %, 95 % CI: 11.2952, 18.4817). Prevalence increased markedly (AAPC: 18.2239 %, 95 % CI: 14.5688, 22.2078), with females at 20.2887 % (95 % CI: 16.6453, 24.3006) and males at 18.1837 % (95 % CI: 14.6734, 21.841). YLDs and YLLs followed similar patterns, with females consistently showing higher AAPCs. Joinpoint analysis identified peak APCs in the 1990s and early 2000s, followed by moderated growth and declines post-2016, particularly from 2019 to 2021, reflecting potential intervention impacts. ARIMA forecasts project a decline in DALYs, deaths, and YLLs ASRs to negligible levels by 2050 for both sexes, with wide CIs indicating substantial uncertainty (e.g., DALYs overall: negligible, 95 % CI: 0, 583.3697). Incidence ASRs are expected to stabilize (e.g., overall: 0.963899, 95 % CI: 0, 3.819279), while prevalence ASRs are projected to rise dramatically, particularly for males (614.7463, 95 % CI: 0, 695680.4), highlighting significant long-term challenges.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;The HIV/AIDS burden in Bangladesh ","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"11 4","pages":"Article 100614"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A liberalized approach to directly observed therapy for HCV retains excellent cure rates among PWID in Vienna","authors":"Caroline Schwarz ,&nbsp;Angelika Schütz ,&nbsp;Maximilian Anibas ,&nbsp;David JM. Bauer ,&nbsp;Lukas Burghart ,&nbsp;Michael Schwarz ,&nbsp;Enisa Gutic ,&nbsp;Thomas Reiberger ,&nbsp;Michael Gschwantler","doi":"10.1016/j.jve.2025.100611","DOIUrl":"10.1016/j.jve.2025.100611","url":null,"abstract":"<div><h3>Introduction</h3><div>Directly observed therapy (DOT) is an effective strategy to optimize hepatitis C virus (HCV) cure rates in people who inject drugs (PWID) on stable opioid agonist therapy (OAT). While adherence to daily DOT is excellent, it remains unclear if extended DOT distribution intervals result in similar sustained virologic response (SVR) rates.</div></div><div><h3>Methods</h3><div>PWID undergoing DOT with direct-acting antiviral agents (DAA) alongside OAT for HCV infection at a low-threshold institution were included. Social distancing requirements during the COVID19 pandemic led to an extension in DOT dispensation intervals; therefore, the study population was classified according to “tight period” (DAA start 2014–2020) and “liberal period” (DAA start 2020–2023) cohorts. Socioeconomic characteristics, DOT distribution schedules, and rates of SVR at week 12 after end of therapy (SVR12) were compared between groups.</div></div><div><h3>Results</h3><div>We included 719 consecutive PWID (male: 76.5 %; median age: 39 years), 441 (61.3 %) were treated in the ”tight period” and 278 (38.7 %) in the “liberal period”. Baseline characteristics were comparable between cohorts, however, socioeconomic features of the “liberal period” group showed more problematic features (unemployment: 83.1 % vs. 67.3 %; lack of housing: 38.5 % vs. 35.1 %; ongoing injection drug use: 64.0 % vs. 57.8 %; each p &lt; 0.001).</div><div>While the “tight period” group had their DAA most commonly dispensed on a daily basis (78.9 %), the “liberal period” group received their DAA/OAT mostly once weekly (45.0 %) or 2-3x/week (24.1 %; p &lt; 0.001). The number of missed DAA ingestions (0.3 % vs. 0.4 %; p = 0.239) and SVR12 rates by modified intention to treat analysis (exclusion of PWID who were lost to follow-up [FU] or died) were similar (401/404, 99.3 % vs. 194/195, 99.5 %; p = 1.000) between tight and liberal period, respectively.</div><div>Loss of FU after end of DAA treatment was more common during the \"liberal period\" (28.8 % vs. 7.9 %; p &lt; 0.001), yet no treatment interruptions or early discontinuations occurred.</div></div><div><h3>Conclusion</h3><div>DOT originally aimed to address non-adherence among PWID by strict control through daily supervised OAT and DAA ingestion. While this approach inherently manifests a position of advanced distrust towards PWID, our findings suggest that a strategy of advanced trust and liberalization of DOT alongside effective harm reduction measures yields excellent adherence and results in similarly high HCV cure rates.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"11 4","pages":"Article 100611"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145268783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discontinuation of nucleos(t)ide analogues after NA-induced HBsAg seroclearance: a single-center 48-week retrospective study","authors":"Yong-Hong Wang,&nbsp;Ya-Chao Tao,&nbsp;Meng-Lan Wang,&nbsp;Cheng-Run Song,&nbsp;Jiang-Nan Peng,&nbsp;En-Qiang Chen","doi":"10.1016/j.jve.2025.100617","DOIUrl":"10.1016/j.jve.2025.100617","url":null,"abstract":"<div><h3>Background</h3><div>Hepatitis B virus (HBV) infection is a major risk factor for liver fibrosis, cirrhosis, and hepatocellular carcinoma. Whether patients with chronic hepatitis B (CHB) receiving oral nucleos(t)ide analogue (NA) therapy can safely discontinue treatment after HBsAg seroclearance is attracting clinical attention.This study aimed to explore the maintenance rate of HBsAg-negative status and the predictors of HBsAg repositivity after drug withdrawal in non-cirrhotic CHB patients who had achieved HBsAg seroclearance following long-term NAs therapy.</div></div><div><h3>Methods</h3><div>This is a single center retrospective study focusing on non-cirrhotic CHB patients who received NAs treatment and achieved HBsAg seroclearance.These patients were treated in the hepatitis clinic of West China Hospital of Sichuan University and followed up for a long time. CHB patients were required to have complete demographic and clinical data. Additionally, serum levels of HBV RNA and HBcrAg were measured in all patients at the time of NAs cessation.</div></div><div><h3>Results</h3><div>A total of 137 non-cirrhotic CHB patients with HBsAg seroclearance were screened. Ultimately, 54 patients agreed to discontinue treatment, while 83 declined. Among the 54 patients who terminated treatment, 43 were male and 11 were female. Of these discontinued patients, 44 received continuous monotherapy, while 10 received combination therapy. All patients in this study received NAs antiviral treatment for more than 5 years. 79.6 % (43/54) of patients were found to be positive for HBsAb and 59.3 % (32/54) of patients had HBsAb≥200 IU/ml at the time of NAs discontinuation. Among the discontinued patients, all 54 patients were HBV RNA negative, and 87.0 % (47/54) were HBcrAg negative.The rates of HBsAg repositive were 3.7 % (95 % CI, 0.6 %–12.7 %) and 9.3 % (95 % CI, 3.8 %–19.7 %) at 24 and 48 weeks after drug withdrawal, respectively, and 3 of them were accompanied by HBV DNA relapse. All patients who regained HBsAg positivity after NAs discontinuation had serum HBcrAg levels greater than 3 log₁₀ U/mL at the time of discontinuation.</div></div><div><h3>Conclusion</h3><div>In this single-center cohort, most non-cirrhotic patients who achieved HBsAg seroclearance on long-term NAs therapy maintained HBsAg loss over 48 weeks after discontinuation. HBcrAg positivity at end of treatment was observed in all cases of HBsAg reappearance, suggesting HBcrAg may help identify patients at higher short-term risk of seroreversion. Larger, longer-term studies are required to confirm these findings.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"11 4","pages":"Article 100617"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2-Deoxyglucose as a therapeutic strategy for EBV-associated gastric carcinoma: Glycolytic and lytic reactivation inhibition under hypoxic conditions","authors":"Yu Du ,&nbsp;Wangsheng Zuo ,&nbsp;Yiting Shao ,&nbsp;Yanying Ji ,&nbsp;Bojin Su ,&nbsp;Sihong Liang ,&nbsp;Deyu Wang ,&nbsp;Bin Li ,&nbsp;Yujie Feng ,&nbsp;Liping Gong ,&nbsp;Jianning Chen ,&nbsp;Chunkui Shao","doi":"10.1016/j.jve.2025.100612","DOIUrl":"10.1016/j.jve.2025.100612","url":null,"abstract":"<div><div>Epstein–Barr virus-associated gastric carcinoma (EBVaGC), a distinct subtype of gastric cancer, accounts for approximately 10 % of all gastric cancer cases. 2-deoxyglucose (2-DG), a glycolysis inhibitor, has emerged as a crucial tool in cancer therapy. However, the differential effects of 2-DG on EBVaGC and EBV-negative gastric carcinoma (EBVnGC) are not yet fully understood. In this study, we demonstrated that 2-DG inhibited the proliferation of both AGS and AGS-EBV cells, with AGS-EBV cells exhibiting greater sensitivity, particularly under hypoxic conditions. Furthermore, EBV infection was found to upregulate glycolytic gene expression in AGS-EBV cells, particularly under hypoxic conditions, through HIF-1α-dependent mechanisms. Notably, 2-DG also inhibited EBV lytic reactivation in AGS-EBV cells under hypoxic conditions. These findings provide valuable insights into the molecular mechanisms of EBV-mediated metabolic reprogramming and highlight the potential of 2-DG as a therapeutic agent for EBVaGC.</div></div>","PeriodicalId":17552,"journal":{"name":"Journal of Virus Eradication","volume":"11 4","pages":"Article 100612"},"PeriodicalIF":2.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}